Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897605 | 0.88 | S1PR5 (0.49) | SCN4APOLBALDH1A1S1PR5S1PR1 | |
| SCHEMBL13041176 | 0.88 | S1PR5 (0.49) | SCN4APOLBALDH1A1S1PR5S1PR1 | |
| SCHEMBL12975924 | 0.84 | FUCA1 (0.53) | SCN4APOLBSIGMAR1ALDH1A1ACHE | |
| Hydrochloric Acid SCHEMBL2883130 | 0.83 | SIGMAR1 (0.54) | SCN4APOLBSIGMAR1ALDH1A1ACHE | |
| SCHEMBL28887854 | 0.82 | BCHE (0.51) | SCN4APOLBLTA4HACHE | |
| SCHEMBL2878305 | 0.81 | SCN4A (0.52) | SCN4APOLBSIGMAR1ACHE | |
| SCHEMBL2878300 | 0.81 | SCN4A (0.52) | SCN4APOLBSIGMAR1ACHE | |
| SCHEMBL2880558 | 0.81 | OPRL1 (0.51) | SCN4APOLBSIGMAR1ALDH1A1ACHE | |
| SCHEMBL2877591 | 0.80 | SLC6A2 (0.52) | SIGMAR1 | |
| SCHEMBL22863935 | 0.79 | LTA4H (0.65) | SCN4ASIGMAR1ALDH1A1S1PR5LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | SCN4A 366/4885POLB 3327/4885SIGMAR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.